Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

NCT04292730 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1113

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Remdesivir
DRUG: Standard of Care

Sponsor

Gilead Sciences